Atterx BioTherapeutics, Inc.

Welcome

BiotechProfiles™ is the premier resource for jobs, company information, professional networking and productivity tools in the Madison, Wisconsin biotechnology and medical device industry. Recognized as one of the premier emerging biotechnology clusters in the U.S., this robust industry sector comprises nearly 10,000 employees in approximately 150 companies. BiotechProfiles also maintains a unique directory of the largest 250 pharmaceutical companies worldwide, including business development contacts whenever available. This tool is indispensable for executives pursuing strategic alliances and technology licenses.
Designed as a suite of easy to use, searchable databases that are continually updated, BiotechProfiles serves the needs of biotech business development and operational executives in early stage companies, as well as the general public. With these tools you can quickly bypass the data collection and screening stage and immediately focus on solving your strategic partnering or operational needs. We've assembled your background data for you!
  Next »

BiotechProfiles is also the premier site for data on Biotechnology Companies in Madison Wisconsin, Biotechnology Jobs in Madison Wisconsin

Biotechnology Companies in Madison Wisconsin; Biotechnology Jobs in Madison Wisconsin
  « Previous | Next »

Biotechnology Business Development, Partnering and Strategic Alliances

Biotechnology Business Development, Partnering and Strategic Alliances
  « Previous | Next »

Madison Biotechnology Companies; Madison Biotechnology Jobs

Madison Biotechnology Companies; Madison Biotechnology Jobs
  « Previous | Next »

List or rank of Largest Pharmaceutical Companies Worldwide

List of rank of Largest Pharmaceutical Companies Worldwide
  « Previous

Advertisement

Company Profile

Atterx BioTherapeutics (formerly ConjuGon) has developed two products to fight multi-drug resistant, Gram negative bacteria. Our first product, C-1205 utilizes bacterial interference technology to prevent catheter associated urinary tract infections. Atterx has an IND on file with the FDA and is poised to enter Phase Ib clinical trials. Atterx’s other core technology consists of using the natural process of bacterial conjugation to treat infection. The product GN-4474 has been developed using this technology to target Gram negative bacteria.
Business Sectors
Pharmaceuticals Human Diagnostics  
Med or Lab Devices   Lab Reagents or Services  
Drug Manufacturing   Food & Agribusiness  
CRO   Bioinformatics or Software  
    Other  
Company History
ConjuGon was founded in 2001 to develop a technology to combat the growing epidemic of antibiotic-resistant bacteria. The technology, based on the work of Dr. Marcin Filutowicz, a Professor in the Bacteriology Department of the University of Wisconsin-Madison, used the naturally-occurring process of conjugation to deliver engineered genes from harmless donor bacteria to targeted, unwanted bacteria. The genes then were expressed in the target and form antibacterial gene products which proceed to kill the unwanted bacteria through multiple and redundant mechanisms. ConjuGon changed its name to Atterx BioTherapeutics Inc. in Dec 2014.

LEADERSHIP ROLL: Sal Braico 2001-2007; Steven Watt PhD 2007-Present
Atterx BioTherapeutics, Inc.
Address 505 South Rosa Road, Suite 29
[Map] Madison
WI
53719
Phone 608-441-2794
Fax
Website Link
Head Steven R. Watt, PhD
Company Statistics
Global Headcount 5
Local Headcount 5
Year Founded 2001
Ownership Private
Stock Exchange

Parent Company
Divisional Level
Senior Level
Global Headcount
Website
Stock Exchange
Reference Documents